Objective Fibromyalgia (FM) frequently co-occurs with SLE, but its independent contribution to musculoskeletal risk is ...

Introduction Patients with SLE have an increased risk of infections and infection-related mortality, which may be associated ...

Objectives To determine the prevalence of cerebral atrophy in a multi-ethnic systemic lupus erythematosus (SLE) cohort and to ...

Objective To apply large language models (LLMs) to Reddit posts referencing SLE to identify patient-expressed unmet medical ...

Background The high heterogeneity in systemic lupus erythematosus (SLE) implies that differential treatment may be required for different patient strata, hence there is an increased need of accurate ...

Fumaric acid esters in cutaneous lupus erythematosus Fumaric acid esters (FAEs), established immunomodulatory agents in the treatment of psoriasis and multiple sclerosis, have been investigated for ...

Objectives A few clinical trials have been performed studying Bruton’s tyrosine kinase (BTK) inhibitors in patients with systemic lupus erythematous (SLE). We evaluate the literature and evidence to ...

An international summit on interferon (IFN) in inflammatory diseases, held in Gaithersburg, Maryland, USA (4–5 May 2017), united 22 internationally renowned clinicians and scientists with backgrounds ...

Objective This study explored the relationship between clinical phenotypes and immuno-molecular features of systemic lupus erythematosus (SLE) using unsupervised machine learning and multi-omics ...

Background AMG 592 is an investigational IL-2 mutein designed for greater regulatory T-cell (Treg) selectivity and longer half-life than recombinant IL-2 (aldesleukin). We investigated the ...

Objectives The REGENCY trial (NCT04221477) demonstrated superiority of obinutuzumab (OBI) plus standard therapy (+ST) vs placebo (PBO) +ST in achieving complete renal response (CRR) at Week 76 (W76) ...

Objective To investigate changes in peripheral B cells, B-cell subsets and biomarkers in NOBILITY. Methods In the randomized Phase II NOBILITY trial (NCT02550652), patients with lupus nephritis ...